444666-41-5

Basic information

• Product Name: 1-(4-METHOXY-PYRIDIN-2-YL)-PIPERAZINE
• Synonyms: 1-(4-METHOXY-PYRIDIN-2-YL)-PIPERAZINE;1-(4-Ethoxy-pyridin-2-yl)-piperazine;1-(4-methoxypyridin-2-yl)piperazine hydrochloride
• CAS NO: 444666-41-5
• Molecular Formula: C₁₀H₁₅N₃O
• Molecular Weight: 193.25
• Mol File: 444666-41-5.mol

Chemical Properties

• Boiling Point: 369.954°C at 760 mmHg
• Flash Point: 177.542°C
• Appearance: /
• Density: 1.105g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: 2-8°C
• PKA: 9.73±0.27(Predicted)
• CAS DataBase Reference: 1-(4-METHOXY-PYRIDIN-2-YL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-METHOXY-PYRIDIN-2-YL)-PIPERAZINE(444666-41-5)
• EPA Substance Registry System: 1-(4-METHOXY-PYRIDIN-2-YL)-PIPERAZINE(444666-41-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 444666-41-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-METHOXY-PYRIDIN-2-YL)-PIPERAZINE is used as a key intermediate in the synthesis of various pharmaceutical drugs, primarily for its role in developing medications with central nervous system activities. Its structural properties allow for the creation of compounds that can modulate neurotransmitter systems, offering potential therapeutic benefits in treating neurological and psychiatric disorders.
Used in Research and Development:
MPP is utilized as a research compound for exploring its potential as an antipsychotic and anxiolytic agent. Its unique chemical structure provides a foundation for investigating novel mechanisms of action and developing new treatment options for mental health conditions. Researchers are particularly interested in its capacity to interact with specific receptors and signaling pathways in the brain, which could lead to the discovery of more effective and safer medications.
Used in Drug Design and Medicinal Chemistry:
1-(4-METHOXY-PYRIDIN-2-YL)-PIPERAZINE is employed as a structural component in drug design and medicinal chemistry. Its heterocyclic nature and functional groups enable the development of diverse chemical entities with potential therapeutic applications. By modifying the substituents and exploring various structural analogs, chemists can optimize the pharmacological properties of MPP-based compounds, enhancing their efficacy, selectivity, and safety profiles.

InChI:InChI=1/C10H15N3O/c1-14-9-2-3-12-10(8-9)13-6-4-11-5-7-13/h2-3,8,11H,4-7H2,1H3

Upstream product

• 110-85-0 piperazine 
• 17228-69-2 2-chloro-4-methoxy-pyridine 

Downstream Products

• 1447723-84-3 2-(3,5-bis-(4-fluoro-phenyl)-(1,2,4)triazol-1-yl)-1-(4-(4-methoxy-pyridin-2-yl)-piperazin-1-yl)-ethanone 
• 1443769-41-2 2-(1,4-bis-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(4-(4-methoxypyridin-2-yl)piperazin-1-yl)ethanone 

Relevant articles and documents

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents

The invention relates to arylpiperazine-benzoylamide derivatives of formula (I) wherein A, X1, X2, n and R1 to R10 are defined as in claim 1, which are suitable for the treatment of diseases characterized by exc

Substituted piperazines

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.